Literature DB >> 14759642

Implications for hyperhomocysteinemia: not homocysteine but its oxidized forms strongly inhibit neuronal network activity.

Philipp Görtz1, Annika Hoinkes, Wiebke Fleischer, Frauke Otto, Bernd Schwahn, Udo Wendel, Mario Siebler.   

Abstract

Severe hyperhomocysteinemia (50-200 microM) often presents itself with acute neuronal dysfunction including seizures and psychosis. Its moderate form (15-50 microM) is associated with cognitive impairment and dementia. We investigated the neuropharmacological effects of homocysteine and its oxidized forms, homocysteinesulfinic acid (HCSA) and homocysteic acid (HCA), on neuronal network function utilizing dissociated cortical neurons from embryonic Wistar rats on microelectrode arrays. All substances inhibited dose-dependently and reversibly spontaneous neuronal network activity within seconds: L-HCSA and L-HCA blocked spontaneous spike rate (SSR) significantly at very low concentrations, with an IC50 of 1.9 and 1.3 microM, respectively; whereas the dose-response curve of D,L-homocysteine revealed an IC50 of 401 microM. These effects were antagonized by 2-amino-5-phosphonovaleric acid (APV) pointing to the NMDA receptor as mediator of this fast and reversible inhibition of network activity. We conclude that a neuronal dysfunction observed in hyperhomocysteinemia is likely due to HCSA and HCA since effective concentrations of homocysteine are not reached in patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14759642     DOI: 10.1016/j.jns.2003.11.009

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Transient reduction of spontaneous neuronal network activity by sublethal amyloid beta (1-42) peptide concentrations.

Authors:  Philipp Görtz; Jessica Opatz; Mario Siebler; Susanne Aileen Funke; Dieter Willbold; Christian Lange-Asschenfeldt
Journal:  J Neural Transm (Vienna)       Date:  2009-02-13       Impact factor: 3.575

2.  Memantine protects rats treated with intrathecal methotrexate from developing spatial memory deficits.

Authors:  Peter D Cole; Veena Vijayanathan; Nafeeza F Ali; Mark E Wagshul; Eric J Tanenbaum; Jeremy Price; Vidhi Dalal; Maria E Gulinello
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

3.  Novel Therapy of Hyperhomocysteinemia in Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementing Disorders.

Authors:  J Hara; W R Shankle; L W Barrentine; M V Curole
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

Review 4.  Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID).

Authors:  Atticus H Hainsworth; Natalie E Yeo; Erica M Weekman; Donna M Wilcock
Journal:  Biochim Biophys Acta       Date:  2015-12-09

5.  Risk of dementia associated with elevated plasma homocysteine in a latin american population.

Authors:  Inara J Chacón; Aldrín E Molero; Gloria Pino-Ramírez; José A Luchsinger; Joseph H Lee; Gladys E Maestre
Journal:  Int J Alzheimers Dis       Date:  2009-08-23

Review 6.  Hyperhomocysteinemia: Metabolic Role and Animal Studies with a Focus on Cognitive Performance and Decline-A Review.

Authors:  Hendrik Nieraad; Nina Pannwitz; Natasja de Bruin; Gerd Geisslinger; Uwe Till
Journal:  Biomolecules       Date:  2021-10-19

7.  Low Vitamin B12 Levels: An Underestimated Cause Of Minimal Cognitive Impairment And Dementia.

Authors:  Shazia Jatoi; Abdul Hafeez; Syeda Urooj Riaz; Aijaz Ali; Muhammad Ishaq Ghauri; Maham Zehra
Journal:  Cureus       Date:  2020-02-13

8.  Impact of Hyperhomocysteinemia and Different Dietary Interventions on Cognitive Performance in a Knock-in Mouse Model for Alzheimer's Disease.

Authors:  Hendrik Nieraad; Natasja de Bruin; Olga Arne; Martine C J Hofmann; Mike Schmidt; Takashi Saito; Takaomi C Saido; Robert Gurke; Dominik Schmidt; Uwe Till; Michael J Parnham; Gerd Geisslinger
Journal:  Nutrients       Date:  2020-10-23       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.